Taiwan National Health Insurance Administration of the Ministry of Health and Welfare Approves Vemlidy(R) (tenofovir alafenamide) for Reimbursement

By In The News
April 30, 2019 in The Headlines

Recommended Posts

In The News

Posted April 30, 2019

- Share

Posted April 30, 2019

TAIPEI, Taiwan, April 29, 2019 /PRNewswire/ -- Gilead Sciences, Inc. today announced that with effect from 1 May 2019, Vemlidy (tenofovir alafenamide, TAF) 25 mg, a once-daily treatment for chronic hepatitis B in adults with compensated liver disease will be made available to patients via ...

View the full article

Link to comment

Share on other sites

Archived

This topic is now archived and is closed to further replies.

Go to topic listing

Most Contributions
1. In The News
  222008
2. Jaydee
  17783
3. deicer
  13345
4. Kip Powick
  12311
5. dagger
  9614
Tell a friend
Love The Airline Website? Tell a friend!
- Email
- Share
Forum Statistics
- Total Topics
  
  272.4k
- Total Posts
  
  565k

Sign In

Taiwan National Health Insurance Administration of the Ministry of Health and Welfare Approves Vemlidy(R) (tenofovir alafenamide) for Reimbursement

Recommended Posts

In The News

Link to comment

Share on other sites

Archived

Most Contributions

Tell a friend

Forum Statistics

Browse

Activity

Support